Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An announcement from Lytix Biopharma AS ( (DE:6BG) ) is now available.
Lytix Biopharma has announced the resignation of Marie Roskrow, the Chair of the Board of Directors, following the Nomination and Compensation Committee’s recommendations for board elections and remuneration. Roskrow’s leadership has been pivotal in guiding the company through a crucial development phase, positioning it for future success.
More about Lytix Biopharma AS
Based in Oslo, Norway, Lytix Biopharma is a clinical-stage biotech company specializing in host-defense peptide-derived molecules. Its lead product, LTX-315, is an innovative oncolytic molecule designed to enhance anti-cancer immunity, with a pipeline capable of addressing various cancer indications and treatment settings.
YTD Price Performance: -14.79%
Technical Sentiment Signal: Buy
Current Market Cap: €28.63M
See more data about 6BG stock on TipRanks’ Stock Analysis page.